Saturday 17 October 2026
Export LUCY’s income statement to Excel — free account
Innovative Eyewear, Inc.
LUCY Healthcare Medical Instruments & Supplies
Innovative Eyewear, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 million, up 62.7% from fiscal 2024. In the quarter to June 2026, revenue grew 74.5%, EPS grew 60.6%, free cash flow grew 9.61% and total debt fell 92.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.79
0.05
−5.95%
Follow LUCY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.93 | 1.50 | 2.28 | 1.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.28) | (2.96) | (2.73) | (2.68) | |
P/B ratio |
0.92 | 0.44 | 0.81 | 0.72 | |
Price to Tangible BV |
0.96 | 0.47 | 0.88 | 0.80 | |
EV/Sales |
0.63 | (0.91) | 0.41 | 0.39 | |
EV/EBITDA |
0.00 | 0.29 | 0.00 | 0.00 | |
EV/Operating CF |
(0.19) | 0.33 | (0.16) | (0.18) | |
EV/FCF |
(0.18) | 0.32 | (0.16) | (0.17) | |
Quick Ratio |
9.13 | 6.36 | 5.27 | 6.89 | |
Current Ratio |
11.98 | 9.03 | 8.02 | 12.06 | |
Net Debt/EBITDA |
4.21 | 2.63 | 2.41 | 2.23 | |
Debt/Assets |
0.36% | 0.28% | 0.22% | 0.05% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.21 | 0.27 | 0.34 | 0.35 | |
Operating CF/Net income |
0.82 | 0.72 | 1.08 | 1.12 | |
Capex/Depreciation |
(0.52) | (5.87) | (1.97) | (1.68) | |
Research and Development Expense of Revenue |
19.46% | 12.15% | 17.85% | 14.06% | |
Selling, General and Administrative Expense of Revenue |
299.46% | 256.55% | 306.89% | 175.20% | |
Intangible Assets out of Total Assets |
0.04 | 0.06 | 0.06 | 0.08 | |
Share Based Compensation of Revenue |
28.39% | 21.48% | 25.98% | 19.62% | |
Graham Net Nets |
1.03 | 2.09 | 1.12 | 1.24 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(112.44%) | (204.00%) | (155.05%) | (165.38%) | |
Free Cash Flow Yield |
(87.34%) | (189.86%) | (114.29%) | (151.29%) | |
Revenue per Share |
0.14 | 0.24 | 0.12 | 0.16 | |
Operating CF per Share |
(0.31) | (0.34) | (0.40) | (0.29) | |
Capex per Share |
0.00 | (0.05) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.31) | (0.39) | (0.41) | (0.30) | |
Cash per Share |
1.64 | 1.63 | 0.91 | 0.58 | |
Shareholders Equity per Share |
2.10 | 2.27 | 1.34 | 1.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.10 | 2.27 | 1.34 | 1.08 | |
Free Cash Flow |
(1.51) | (1.54) | (2.55) | (1.91) | |
Working Capital |
9.71 | 8.39 | 7.66 | 6.22 | |
Capital Expenditures |
(0.01) | (0.19) | (0.06) | (0.05) | |
Net Current Asset Value |
9.67 | 8.36 | 7.64 | 6.21 | |
EV/EBIT |
0.00 | 0.29 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.20 | 0.07 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.08 | 0.13 | 0.08 | 0.10 | |
Average Payables |
0.69 | 0.84 | 0.68 | 0.49 | |
Average Inventory |
1.61 | 1.72 | 1.80 | 2.10 | |
Average Assets |
11.39 | 9.99 | 8.71 | 9.70 | |
Average Common Equity |
10.59 | 9.08 | 7.93 | 9.09 |
Columns are period end dates